Jordi S Silvestre

Summary

Affiliation: Prous Science
Country: Spain

Publications

  1. ncbi request reprint Opposite effects of ethanol and ketamine in the elevated plus-maze test in Wistar rats undergoing a chronic oral voluntary consumption procedure
    Jordi S Silvestre
    Prous Science SA, Barcelona, Spain
    J Psychopharmacol 16:305-12. 2002
  2. ncbi request reprint Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes
    J S Silvestre
    Department of Pharmacology, Prous Science, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 27:289-304. 2005
  3. ncbi request reprint Comparative evaluation of hERG potassium channel blockade by antipsychotics
    J S Silvestre
    Department of Pharmacology, Prous Institute for Biomedical Research and Prous Science, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 29:457-65. 2007

Detail Information

Publications3

  1. ncbi request reprint Opposite effects of ethanol and ketamine in the elevated plus-maze test in Wistar rats undergoing a chronic oral voluntary consumption procedure
    Jordi S Silvestre
    Prous Science SA, Barcelona, Spain
    J Psychopharmacol 16:305-12. 2002
    ..On the other hand, the lack of effects from mixed solution consumption suggests that EtOH and KET may interact in such a way that their effects are neutralized...
  2. ncbi request reprint Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes
    J S Silvestre
    Department of Pharmacology, Prous Science, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 27:289-304. 2005
    ..This study is the first in a series of investigations that aim to further our understanding of mechanisms underlying adverse drug effects...
  3. ncbi request reprint Comparative evaluation of hERG potassium channel blockade by antipsychotics
    J S Silvestre
    Department of Pharmacology, Prous Institute for Biomedical Research and Prous Science, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 29:457-65. 2007
    ..Thus, their cardiotoxic risk will be discussed on the basis of their hERG-blocking properties and previous clinical data when available...